Alpha 2.0
Login Register
» Authors » Pierre Tennstedt

Pierre Tennstedt

Explore the profile of Pierre Tennstedt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 106
Citations 2017
Followers 0
Related Specialties
Urology
Oncology
Pathology
Top 10 Co-Authors
Markus Graefen
Thorsten Schlomm
Thomas Steuber
Derya Tilki
Hartwig Huland
Georg Salomon
Guido Sauter
Hans Heinzer
Ronald Simon
Lars Budaus
Published In
World J Urol
BJU Int
Eur Urol
Urol Oncol
Eur Urol Focus
Affiliations
Soon will be listed here.
Recent Articles
11.
[Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers]
Kowalski C, Sibert N, Hammerer P, Wesselmann S, Feick G, Carl E, et al.
Urologie . 2023 Sep; 63(1):67-74. PMID: 37747493
Background: In addition to erectile dysfunction, urinary incontinence is the most common functional limitation after radical prostatectomy (RPE) for prostate cancer (PCa). The German S3 guideline recommends informing patients about...
12.
Outcome of patients with epithelialized cavity formation after excessive vesicourethral anastomotic leak post radical prostatectomy
Filipas D, Graefen M, Fisch M, Steuber T, Heinzer H, Schulz R, et al.
World J Urol . 2023 Jul; 41(9):2327-2333. PMID: 37450007
Purpose: Excessive vesicourethral anastomotic leak (EVAL) is a rare but severe complication after radical prostatectomy (RP). Epithelialized vesicourethral cavity formation (EVCF) usually develops during prolonged catheterization. To our knowledge, there...
13.
Advances, Limitations and Future Challenges in the Management of Immunotherapy for Hematological Diseases and Solid Tumors
Tennstedt P, Oh-Hohenhorst S
Int J Mol Sci . 2023 May; 24(10). PMID: 37240158
Our immune system is able to attack cancer cells by recognizing cellular mistakes and destroying them [...].
14.
Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle program
Thederan I, Pott A, Krueger A, Chandrasekar T, Tennstedt P, Knipper S, et al.
Prostate . 2023 Apr; 83(10):929-935. PMID: 37051922
Background: Prostate cancer (PCa) is the most frequently diagnosed malignant tumor in men. The potential benefit of a healthy lifestyle contrasts sharply with the observed poor adherence to current international...
15.
A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer
Gentile F, La Civita E, Della Ventura B, Ferro M, Bruzzese D, Crocetto F, et al.
Cancers (Basel) . 2023 Mar; 15(5). PMID: 36900150
Background: The Prostate Health Index (PHI) and Proclarix (PCLX) have been proposed as blood-based tests for prostate cancer (PCa). In this study, we evaluated the feasibility of an artificial neural...
16.
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Guldvik I, Braadland P, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, et al.
Eur Urol Open Sci . 2022 Nov; 45:68-75. PMID: 36353660
Background: After radical prostatectomy (RP), depending on stage, up to 40% of patients with prostate cancer (PCa) will experience biochemical failure (BF). Despite salvage therapy, approximately one-third of these patients...
17.
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index
Terracciano D, La Civita E, Athanasiou A, Liotti A, Fiorenza M, Cennamo M, et al.
Prostate . 2022 Aug; 82(15):1469-1476. PMID: 35971798
Objectives: Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for...
18.
Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery
Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, et al.
Eur Urol . 2022 Jun; 83(1):62-69. PMID: 35718637
Background: In a subset of patients with recurrent oligometastatic prostate cancer (PCa) salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance (PSMA-RGS) might be of value. Objective: To evaluate the oncological...
19.
Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer
Klocker H, Golding B, Weber S, Steiner E, Tennstedt P, Keller T, et al.
BJUI Compass . 2022 Apr; 1(1):15-20. PMID: 35474911
Objectives: Selecting patients suspected of having prostate cancer (PCa) for a prostate biopsy remains a challenge. Prostate-specific antigen (PSA)-based testing is hampered by its low specificity that often leads to...
20.
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
Athanasiou A, Tennstedt P, Wittig A, Huber R, Straub O, Schiess R, et al.
PLoS One . 2021 Nov; 16(11):e0259093. PMID: 34767586
The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men...